CHMMF vs REGN: Which Stock is Better?
Side-by-side comparison of Chimeric Therapeutics Limited and Regeneron Pharmaceuticals Inc in 2026
CHMMF
Chimeric Therapeutics Limited
$0.00
REGN
Regeneron Pharmaceuticals Inc
$750.57
Key Metrics Comparison
| Metric | CHMMF | REGN | Winner |
|---|---|---|---|
| Market Cap | $4.42M | $79.35B | REGN |
| P/E Ratio | N/A | 18.08 | REGN |
| EPS (TTM) | $N/A | $41.51 | REGN |
| Revenue Growth | -0.5% | 0.0% | REGN |
| Gross Margin | 91.3% | 44.6% | CHMMF |
Analyze CHMMF
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHMMF or REGN a better investment?
Comparing CHMMF and REGN: Chimeric Therapeutics Limited has a market cap of $4.42M while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHMMF and REGN?
CHMMF (Chimeric Therapeutics Limited) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHMMF or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHMMF or REGN?
REGN has higher revenue growth at 0.0% vs -0.5% for CHMMF.
Which company is more profitable: CHMMF or REGN?
Chimeric Therapeutics Limited (CHMMF) has higher gross margins at 91.3% compared to 44.6% for REGN.
Which is the larger company: CHMMF or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $4.42M for CHMMF.
Should I buy CHMMF or REGN in 2026?
Both CHMMF and REGN have investment merit. CHMMF trades at $0.00 while REGN trades at $750.57. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHMMF and REGN stock?
Key differences: Market Cap ($4.42M vs $79.35B), P/E Ratio (N/A vs 18.1x), Revenue Growth (-0.5% vs 0.0%), Gross Margin (91.3% vs 44.6%).